355 related articles for article (PubMed ID: 22685175)
21. Inhibition of mTORC1/C2 signaling improves anti-leukemia efficacy of JAK/STAT blockade in
Zhang Q; Shi C; Han L; Jain N; Roberts KG; Ma H; Cai T; Cavazos A; Tabe Y; Jacamo RO; Mu H; Zhao Y; Wang J; Wu SC; Cao F; Zeng Z; Zhou J; Mi Y; Jabbour EJ; Levine R; Tasian SK; Mullighan CG; Weinstock DM; Fruman DA; Konopleva M
Oncotarget; 2018 Jan; 9(8):8027-8041. PubMed ID: 29487712
[TBL] [Abstract][Full Text] [Related]
22. Combination efficacy of ruxolitinib with standard-of-care drugs in CRLF2-rearranged Ph-like acute lymphoblastic leukemia.
Bӧhm JW; Sia KCS; Jones C; Evans K; Mariana A; Pang I; Failes T; Zhong L; Mayoh C; Landman R; Collins R; Erickson SW; Arndt G; Raftery MJ; Wilkins MR; Norris MD; Haber M; Marshall GM; Lock RB
Leukemia; 2021 Nov; 35(11):3101-3112. PubMed ID: 33895784
[TBL] [Abstract][Full Text] [Related]
23. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.
Hertzberg L; Vendramini E; Ganmore I; Cazzaniga G; Schmitz M; Chalker J; Shiloh R; Iacobucci I; Shochat C; Zeligson S; Cario G; Stanulla M; Strehl S; Russell LJ; Harrison CJ; Bornhauser B; Yoda A; Rechavi G; Bercovich D; Borkhardt A; Kempski H; te Kronnie G; Bourquin JP; Domany E; Izraeli S
Blood; 2010 Feb; 115(5):1006-17. PubMed ID: 19965641
[TBL] [Abstract][Full Text] [Related]
24. Characterization of Philadelphia-like Pre-B Acute Lymphoblastic Leukemia: Experiences in Mexican Pediatric Patients.
Martínez-Anaya D; Moreno-Lorenzana D; Reyes-León A; Juárez-Figueroa U; Dean M; Aguilar-Hernández MM; Rivera-Sánchez N; García-Islas J; Vieyra-Fuentes V; Zapata-Tarrés M; Juárez-Villegas L; Paredes-Aguilera R; Vega-Vega L; Rivera-Luna R; Juárez-Velázquez MDR; Pérez-Vera P
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076986
[TBL] [Abstract][Full Text] [Related]
25. JAK-STAT and JAK-PI3K-mTORC1 pathways regulate telomerase transcriptionally and posttranslationally in ATL cells.
Yamada O; Ozaki K; Akiyama M; Kawauchi K
Mol Cancer Ther; 2012 May; 11(5):1112-21. PubMed ID: 22402124
[TBL] [Abstract][Full Text] [Related]
26. Correlation of the surface expression of thymic stromal lymphopoietin receptor with the presence of CRLF2 gene rearrangements in children with B-lineage acute lymphoblastic leukemia.
Demina I; Zerkalenkova E; Soldatkina O; Kazakova A; Semchenkova A; Goncharova M; Novichkova G; Maschan M; Karachunskiy A; Olshanskaya Y; Popov A
Int J Lab Hematol; 2023 Jun; 45(3):337-343. PubMed ID: 36748719
[TBL] [Abstract][Full Text] [Related]
27. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.
Russell LJ; Capasso M; Vater I; Akasaka T; Bernard OA; Calasanz MJ; Chandrasekaran T; Chapiro E; Gesk S; Griffiths M; Guttery DS; Haferlach C; Harder L; Heidenreich O; Irving J; Kearney L; Nguyen-Khac F; Machado L; Minto L; Majid A; Moorman AV; Morrison H; Rand V; Strefford JC; Schwab C; Tönnies H; Dyer MJ; Siebert R; Harrison CJ
Blood; 2009 Sep; 114(13):2688-98. PubMed ID: 19641190
[TBL] [Abstract][Full Text] [Related]
28. Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions.
Sadras T; Heatley SL; Kok CH; Dang P; Galbraith KM; McClure BJ; Muskovic W; Venn NC; Moore S; Osborn M; Revesz T; Moore AS; Hughes TP; Yeung D; Sutton R; White DL
Cancer Lett; 2017 Nov; 408():92-101. PubMed ID: 28866095
[TBL] [Abstract][Full Text] [Related]
29. RAS-protein activation but not mutation status is an outcome predictor and unifying therapeutic target for high-risk acute lymphoblastic leukemia.
Koschut D; Ray D; Li Z; Giarin E; Groet J; Alić I; Kham SK; Chng WJ; Ariffin H; Weinstock DM; Yeoh AE; Basso G; Nižetić D
Oncogene; 2021 Jan; 40(4):746-762. PubMed ID: 33247204
[TBL] [Abstract][Full Text] [Related]
30. Effects of different aberrations in the CRLF2 gene on the biological characteristics and drug sensitivities of Nalm6 cells.
Gu M; Jia Y; Xu M; Feng J; Tian Z; Ma X; Wang M; Wang J; Xu Y; Rao Q; Hao L; Mi Y; Yang W
Int J Lab Hematol; 2021 Jun; 43(3):441-449. PubMed ID: 33615710
[TBL] [Abstract][Full Text] [Related]
31. Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia.
Bugarin C; Sarno J; Palmi C; Savino AM; te Kronnie G; Dworzak M; Shumich A; Buldini B; Maglia O; Sala S; Bronzini I; Bourquin JP; Mejstrikova E; Hrusak O; Luria D; Basso G; Izraeli S; Biondi A; Cazzaniga G; Gaipa G;
Haematologica; 2015 Jun; 100(6):e229-32. PubMed ID: 25862705
[No Abstract] [Full Text] [Related]
32. Hematological characteristics, cytogenetic features, and post-induction measurable residual disease in thymic stromal lymphopoietin receptor (TSLPR) overexpressed B-cell acute lymphoblastic leukemia in an Indian cohort.
Virk H; Rana S; Sharma P; Bose PL; Yadav DD; Sachdeva MUS; Varma N; Trehan A; Lad D; Khadwal AR; Malhotra P; Sreedharanunni S
Ann Hematol; 2021 Aug; 100(8):2031-2041. PubMed ID: 34159401
[TBL] [Abstract][Full Text] [Related]
33. CRLF2 overexpression identifies an unfavourable subgroup of adult B-cell precursor acute lymphoblastic leukemia lacking recurrent genetic abnormalities.
Chiaretti S; Brugnoletti F; Messina M; Paoloni F; Fedullo AL; Piciocchi A; Elia L; Vitale A; Mauro E; Ferrara F; De Fabritiis P; Luppi M; Ronco F; De Propris MS; Raponi S; Kronnie GT; Vignetti M; Guarini A; Foà R
Leuk Res; 2016 Feb; 41():36-42. PubMed ID: 26754556
[TBL] [Abstract][Full Text] [Related]
34. Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.
Guo Y; Shan Q; Gong Y; Lin J; Yang X; Zhou R
Cancer Biol Ther; 2012 Nov; 13(13):1244-54. PubMed ID: 22895079
[TBL] [Abstract][Full Text] [Related]
35. Single-cell profiling of pediatric T-cell acute lymphoblastic leukemia: Impact of PTEN exon 7 mutation on PI3K/Akt and JAK-STAT signaling pathways.
Bonaccorso P; Bugarin C; Buracchi C; Fazio G; Biondi A; Lo Nigro L; Gaipa G
Cytometry B Clin Cytom; 2020 Nov; 98(6):491-503. PubMed ID: 32479694
[TBL] [Abstract][Full Text] [Related]
36. Characterisation of the genomic landscape of CRLF2-rearranged acute lymphoblastic leukemia.
Russell LJ; Jones L; Enshaei A; Tonin S; Ryan SL; Eswaran J; Nakjang S; Papaemmanuil E; Tubio JM; Fielding AK; Vora A; Campbell PJ; Moorman AV; Harrison CJ
Genes Chromosomes Cancer; 2017 May; 56(5):363-372. PubMed ID: 28033648
[TBL] [Abstract][Full Text] [Related]
37. Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenografts.
Fuka G; Kantner HP; Grausenburger R; Inthal A; Bauer E; Krapf G; Kaindl U; Kauer M; Dworzak MN; Stoiber D; Haas OA; Panzer-Grümayer R
Leukemia; 2012 May; 26(5):927-33. PubMed ID: 22094587
[TBL] [Abstract][Full Text] [Related]
38. CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia.
Palmi C; Savino AM; Silvestri D; Bronzini I; Cario G; Paganin M; Buldini B; Galbiati M; Muckenthaler MU; Bugarin C; Della Mina P; Nagel S; Barisone E; Casale F; Locatelli F; Lo Nigro L; Micalizzi C; Parasole R; Pession A; Putti MC; Santoro N; Testi AM; Ziino O; Kulozik AE; Zimmermann M; Schrappe M; Villa A; Gaipa G; Basso G; Biondi A; Valsecchi MG; Stanulla M; Conter V; Te Kronnie G; Cazzaniga G
Oncotarget; 2016 Sep; 7(37):59260-59272. PubMed ID: 27449287
[TBL] [Abstract][Full Text] [Related]
39. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.
Harvey RC; Mullighan CG; Chen IM; Wharton W; Mikhail FM; Carroll AJ; Kang H; Liu W; Dobbin KK; Smith MA; Carroll WL; Devidas M; Bowman WP; Camitta BM; Reaman GH; Hunger SP; Downing JR; Willman CL
Blood; 2010 Jul; 115(26):5312-21. PubMed ID: 20139093
[TBL] [Abstract][Full Text] [Related]
40. Genome-wide CRISPR-Cas9 screen identifies rationally designed combination therapies for CRLF2-rearranged Ph-like ALL.
Sasaki K; Yamauchi T; Semba Y; Nogami J; Imanaga H; Terasaki T; Nakao F; Akahane K; Inukai T; Verhoeyen E; Akashi K; Maeda T
Blood; 2022 Feb; 139(5):748-760. PubMed ID: 34587248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
